ALX Oncology Holdings Inc (ALXO) stock
ALXONasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.02+0.05 (+5.14%)
Close on Nov 19, 2026Market cap $141.04MP/E –Yield –
ALX Oncology operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
ALX Oncology's operating income for the twelve months ending Jun 30, 2026 was -$82.55M. For fiscal 2025 it was -$104.02M. The highest annual figure on record is -$13.68M in fiscal 2018.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$104.02M | – |
| FY2024 | Dec 31, 2024 | -$142.47M | – |
| FY2023 | Dec 31, 2023 | -$170.28M | – |
| FY2022 | Dec 31, 2022 | -$127.44M | – |
| FY2021 | Dec 31, 2021 | -$83.56M | – |
| FY2020 | Dec 31, 2020 | -$43.66M | – |
| FY2019 | Dec 31, 2019 | -$19.18M | – |
| FY2018 | Dec 31, 2018 | -$13.68M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$18.03M | – |
| Q1 FY2026 | Mar 31, 2026 | -$18.97M | – |
| Q4 FY2025 | Dec 31, 2025 | -$23.02M | – |
| Q3 FY2025 | Sep 30, 2025 | -$22.53M | – |
| Q2 FY2025 | Jun 30, 2025 | -$26.65M | – |
| Q1 FY2025 | Mar 31, 2025 | -$31.82M | – |
| Q4 FY2024 | Dec 31, 2024 | -$30.61M | – |
| Q3 FY2024 | Sep 30, 2024 | -$32.57M | – |
| Q2 FY2024 | Jun 30, 2024 | -$41.53M | – |
| Q1 FY2024 | Mar 31, 2024 | -$37.76M | – |
| Q4 FY2023 | Dec 31, 2023 | -$48.02M | – |
| Q3 FY2023 | Sep 30, 2023 | -$53.28M | – |
| Q2 FY2023 | Jun 30, 2023 | -$36.78M | – |
| Q1 FY2023 | Mar 31, 2023 | -$32.20M | – |
| Q4 FY2022 | Dec 31, 2022 | -$32.22M | – |
| Q3 FY2022 | Sep 30, 2022 | -$36.68M | – |
| Q2 FY2022 | Jun 30, 2022 | -$33.79M | – |
| Q1 FY2022 | Mar 31, 2022 | -$24.75M | – |
| Q4 FY2021 | Dec 31, 2021 | -$28.47M | – |
| Q3 FY2021 | Sep 30, 2021 | -$24.58M | – |
| Q2 FY2021 | Jun 30, 2021 | -$16.30M | – |
| Q1 FY2021 | Mar 31, 2021 | -$14.21M | – |
| Q4 FY2020 | Dec 31, 2020 | -$17.83M | – |
| Q3 FY2020 | Sep 30, 2020 | -$9.81M | – |
| Q2 FY2020 | Jun 30, 2020 | -$10.79M | – |
| Q1 FY2020 | Mar 31, 2020 | -$5.24M | – |
| Q4 FY2019 | Dec 31, 2019 | -$7.73M | – |
| Q3 FY2019 | Sep 30, 2019 | -$3.03M | – |
| Q2 FY2019 | Jun 30, 2019 | -$4.19M | – |
See a number that looks wrong?